Design Therapeutics (DSGN) Total Non-Current Liabilities (2020 - 2021)
Design Therapeutics (DSGN) posted quarterly Total Non-Current Liabilities of $8.8 million for Q3 2021, up 157.8% on a QoQ basis from $3.4 million in Q2 2021.
Design Therapeutics (DSGN) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends
Design Therapeutics has reported Total Non-Current Liabilities for 2 years, with the latest figure at $8.8 million in Q3 2021.
- Total Non-Current Liabilities for Q3 2021 came in at $8.8 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $8.8 million (changed N/A YoY), and the FY2020 annual result was $2.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities advanced to $8.8 million in Q3 2021, from $3.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $8.8 million in Q3 2021 and troughed at $2.3 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 8.78 Mn |
| Jun 30, 2021 | 3.41 Mn |
| Mar 31, 2021 | 3.71 Mn |
| Dec 31, 2020 | 2.33 Mn |